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BONE MARROW (BM) augmentation of donor-derived chimerism was achieved in recipients of kid-
ney. liver. heart. and pancreas islet transplantation. l We 
have proposed that these donor-derived cells are essential 
for graft acceptance and the induction of donor-specific 
nonreactivity.2.3 The first 15 BM-augmented transplant 
recipients and 16 nonmarrow controls who were more than 
120 days posttransplant underwent sequential in vitro im-
munological evaluations to determine the development of 
donor-specific hyporeactivity.4 Based on proliferative re-
sponses (pre- and posttransplant) of peripheral blood 
mononuclear cells (PBMCs) to mitogens and alloantigens. 
the recipients were classified into four categories: donor-
specific hyporeactive. intermediate. responsive. and sup-
pressed.4 Fifty-three percent of BM treated recipients 
(eight of 15) exhibited progressive modulation of antidonor 
responses. whereas only 12% of nonmarrow controls 
showed donor-specific hyporeactivity. However. the fol-
low-up time in the nonmarrow control group was shorter 
(112 ::: 10 days) as compared with that of patients in the 
study group (282 ::t: 113 days).4 In this report. we reanalyzed 
the immune profile of BM-treated and nonmarrow controls 
3 months later. and the results were compared with the 
earlier report. 
METHODS 
Case Material 
Since December 1992. 64 patients have received simultaneous 
8M-positive whole-organ transplants. whereas 53 recipients of 
whole organs alone have been monitored as contemporaneous 
controls. However. the present study included 17 of 19 BM-
augmented recipients (kidneys. n = 6: kidney plus islets. n = 2; 
livers. n = 7; liver plus islets. n = 1: and heart. n = 1) and 22 of 25 
nonmarrow controls (kidneys. n = 6; livers. n = 14: and hearts, 
n .. 2) who were more than 120 days posttransplant and in whom 
in vitro immune monitoring was possible. Immunosuppression was 
aimilar in both groups and consisted of FK 506 and prednisone 
routinely used at our center. I Using HLA-specific markers and 
probes for Y chromosome (in male to female transplant recipi-
ents), all patients were examined for donor chimerism by fluores-
cence-activated cell sorting (FACS). fluorescence in situ hybridiza-
tion (FISH), and polymerase chain reaction (PCR).I 
In Vitro Immune Monitoring 
Recipients' PBMCs were prepared via a method described previ-
ously, were tested for proliferative responses induced by mitogens 
(phytohemagglutinin [PHAI and concanavalin A [Con A» and by 
aIIoantigens (donor and third-party panel cells) in mixed lympho-
Cyte reaction (MLR) assays, the details of which were summarized 
eiscwhere.5." . 
Based on the proliferative responses of recipients' PBMCs pre-
and posttransplantation. we have classified them into four catego-
ries." 
Category r. Donor-specific hyporeactive: significant decrease (over 
70%) in posttransplant versus pre transplant donor-specific MLR 
responses while maintaining adequate reactivity to control third 
party stimulator cells and mitogens. 
Category II. Donor-specific intermediate: reduction (40% to 70%) 
in posttransplant donor-specific alloreactivity as compared with 
pre transplant baseline control. with no attenuation of respon-
siveness to third-party stimulators or mitogens. 
Category III. Reactive: minimal change in pre transplant versus 
posttransplant donor-specific reactivity. 
Category IV. Suppressed: global nonreactivity to all in vitro stimuli. 
RESULTS 
Distribution of Donor-Specific MLR Patterns in 
8M-Augmented and Control Transplant Recipients 
The overall percentage of donor-specific hyporeactive/in-
termediate responders in the BM-augmented and control 
groups remained similar to that reported 3 months earlier 
(53% and 12% versus 41 % and 18%. respectively) (Table 
1). In the current analysis. five of eight BM/liver recipients 
(62%) exhibited modulation of donor-specific reactivity 
(four hyporeactive and one intermediate), whereas in the 
control group only three of 14 patients (21%) showed a 
reduction in antidonor reactivity (three intermediate). BMI 
kidney and kidney control recipients had a similar distribu-
tion of donor-specific nonreactivity (25% and 16%, respec-
tively). Furthermore. all control recipients who previously 
exhibited global nonreactivity (kidneys. n = 2; livers. n = 2) 
regained their in vitro immune responsiveness and became 
reactive to donor cells (Table 1). 
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Table 1. Donor-8pecific MLR Patterns in BM-Augmented and Control Transplant Recipients 
Report 
Paned 
April 1994 
July 1994 
Groups 
(POD:!: SO)" nt 
With 8M 15 
(150 :: 60) 
Without 8M 16 
(112 :: 10) 
With 8M 17 
(2B5 = 119) 
Without 8M 22 
(153 = 74) 
'Postoperatlve day when last sample was tested. 
t Number of recIpIents per group. 
Hyporeactlve 
20 
(1K.2l)t 
12 
(1K.1l)i 
29 
(1 K. 4l)i 
0 
iNumber of transplant recIpIents for each organ: K. kidney; L hver. H. heart. 
Immune Reactivity. Immunosuppression, and Chimerism 
As shown in Tables 2 and 3, the number of patients off 
steroids was higher in the kidney and liver (66% and 75%, 
respectively) transplant recipients who also exhibited di-
minished donor-specific MLR responses than in the donor-
reactive patients (0% and 43% respectively) in both BM-
augmented and nonaugmented groups. 
Chimerism in the BM-augmented group was detectable 
by flow cytometry for up to 18 months after transplantation 
and ranged between 0.5% and 2.6% in both the hyporeac-
tive and donor-reactive recipients. whereas in the majority 
of the control recipients detection of donor cells by FACS 
analysis yielded negative results 30 to 60 days posttransplant 
(donor-derived cells accounted for less than 0.5%) (Tables 
2 and 3). 
Shift in Donor-Specific Reactivity 
Four BM-treated recipients (two livers. one with pancreatic 
islets; and two kidneys. one with islets) who exhibited early 
evidence of donor-specific hyporeactive or intermediate 
reactivity reverted into reactive against the donor when last 
tested. In three of four patients. we also have evidence of an 
increase (three- to lO-fold) in circulating donor-specific 
helper T cells (data not shown). All four recipients experi-
enced late rejection episodes. Heightened donor-specific 
Table 2. Correlation Between Immune Reactivity, 
Immunosuppression, and Chimerism: Kidney 
Transplant Recipients 
Immunosuppression Chimensm (%) 
MLR Reactivity 
Profile 
FK Level 
(ng/mL) 
Hyporesponslve/intermediate 
01! 
PrednIsone 
Study (n = 2) 0.1, O.B 1/2 
Control (n = 1) 0.9 1/1 
ResponSive 
Study (n = 6) 
Control (n = 5) 
1.0 = 0.5 
0.9:!: 0.4 
'Level of circulating dOnot' cells. 
T Percentage of patIents positIve. 
NF. not feeslble. 
0/6 
0/5 
FACS' PCRt 
1.9,0.5 100 
0.83 NF 
0.5-2.6 100 
<0.5 60 
DistributIon of MLR Profiles (%) 
IntermedIate ReactIve SuppreSSed 
33 47 0 
(2K 3l)t (4K. 2L. 1 H)t 
0 63 25 
(2K.8l)t (2K.2l)i 
12 59 0 
(1 K. 1L)t (6K. 3L. 1 H)t 
1B B2 0 
(1 K. 3L)t (5K. 11 L. 2H)t 
reactivity was maintained in three of four (liver plus islet. 
n = 1; kidney, n = 1; and kidney plus islet. n = 1) recipients 
after resolution of their ongoing rejection. whereas one 
liver patient reverted to being hyporeactive to the donor. 
The kidney recipient who was treated for recurrent latl: 
rejection episode exhibited antidonor alloreactivity before 
initiation of antirejection and after steroid recycle. The 
specificity of this response was confirmed when lymphocyte 
cultures propagated from pre- and posttherapy samples in 
bulk MLRs also exhibited vigorous proliferation to the 
donor-mismatched HLA class II DR! antigen (data not 
shown). Furthermore. the prerejection lymphocyte culture 
exhibited cell-mediated lymphocylolOXicity against donor 
lymphoblastoid B cells (data not shown). 
DISCUSSION 
The recognition that after whole-organ transplantation 
resident bone-marrow derived cells migrate out of the graft 
into the recipient and persist has led to the concept that 
establishment of chimerism is a seminal event in allograft 
acceptance and subsequent induction of donor-specific 
hyporeactivity. :.3 This spontaneous chimerism was safely 
augmented by simultaneous infusion of bone-marrow along 
with whole-organ transplants. I The in vitro immune reac-
tivity profile of patients in the BM-augmented group was 
reminiscent of earlier observations in recipients of long-
Table 3. Correlation Between Immune Reactivity, 
Immunosupprassion, and Chimerism: Liver 
Transplant Recipients 
ImmunosuppressIon ChimerIsm % 
MLR Reactivity FK Level 01! 
Profile (nglmL) Prednisone FACS' PCRt 
Hyporesponslvelintermediate 
Study (n = 5) 0.4 = 0.3 3/5 0.5-2.5 100 
Control (n = 3) 0.4=0.1 3/3 NF 66 
Responsive 
Study (n = 3) 0.3 = 0.1 1/3 0.5-2.3 100 
Control (n = 11) 0.7 = 0.2 5/11 1.3. <0.5 56 
'Level of circulating donor cells. 
'Percentage of patIents posItIve. 
NF. not feasible. 
J 
islet, 
Jients 
. one 
oor. 
t late 
dore 
The 
ocyte 
les in 
I the 
I not 
Iiture 
lonor 
ation 
graft 
: that 
19raft 
ecific 
;afely. 
along 
reac-
lWas 
long-
1% 
100 
66 
100 
56 
SERIAL EVALUATION OF IMMUNE PROFILES 
term functioning allografts who exhibited donor-specific 
hyporeactivity.7-" However. in the 8M-treated recipients 
these changes occurred more frequently and earlier than in 
Ihe contemporaneous controls. 4 
\on!!cr follow-up of both 8M- and non-marrow-treated 
Iln:r recipients demonstrated that the 8M augmentation 
ILl' conhrmed an advantage because five of eight (62'i~) 
pro!!ressed to stable donor-specific hypo reactive status, 
whereas only 21 'ic of recipients of liver allograft alone 
exhihited donor-specific intermediate responses. These re-
sult~ suggest that the inherent tolerogenecity of liver ai-
1(J~rafts can be further enhanced by simultaneous 8M 
infusion. 
I n contrast to liver recipients, BM-enriched and control 
kidney rccipients had a similar pattern of donor-specific 
hyporeactivity that was maintained over the course of our 
follow-up. Nevertheless. the graft function of marrow-
au!!mented kidney recipients was significantly better as 
l'Ompared with that of the controls. lo 
OJ nole is that none of the BM-treated or control 
rl'l'lpil'nts when last tested exhibited universal nonreactivity 
;lIld all of the previous recipients in the control group who 
II L'rL' classified as suppressed reverted to become donor 
reactIve. 4 
In summary. BM infusion with whole-organ transplanta-
215 
tion proved to be a safe procedure to augment donor 
chimerism in transplant recipients. l Serial immunologic 
examinations of these recipients may help us \0 better 
understand the role of both immune systems (donor and 
recipient) in establishing allograft acceptance and lolcr-
ance. 
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